Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ebhcCduTtWCfhfjaCidncVCicNxpwK
| Today's Top Story |  |  | | - Report: 73 drugs, vaccines being developed for AIDS, HIV
Drugmakers are developing at least 73 drugs or vaccines for patients with AIDS and HIV, according to a PhRMA report, and pharma innovation is changing the disease from a death sentence to a manageable condition, another report found. "Incredible strides have been made in the battle against HIV/AIDS, but the disease still poses a global threat, and the collaborative path to further solutions for patients will be complex," PhRMA CEO John J. Castellani said. "The nearly 75 medicines in development offer great hope for better treatment and prevention of HIV/AIDS in the years ahead." Drug Store News (11/29)       | Health Care & Policy | | | | - Theravance's Vibativ gains partial support from FDA panel
An FDA advisory panel endorsed the approval of Theravance's once-daily antibiotic Vibativ to treat patients with hospital-acquired pneumonia when other alternatives are not suitable. But the drug failed to win the advisory committee's approval recommendation as a first-line therapy for the condition, also known as nosocomial pneumonia. Trial data failed to offer "substantial evidence" of Vibativ's safety and efficacy against hospital-acquired pneumonia, the panel said. American City Business Journals/San Francisco/BiotechSF blog (11/30) - DARA files orphan-drug application for chemo pain drug
DARA BioSciences submitted an application to the FDA seeking orphan-drug designation for KRN5500, an experimental treatment for a painful form of chronic chemotherapy-induced peripheral neuropathy. A midstage trial showed that KRN5500 is statistically and clinically superior over placebo in treating patients with both a painful form of CCIPN and advanced cancer. Pharmaceutical Business Review Online (11/30) - Tekmira will use Marina's technology to develop RNAi drugs
Marina Biotech granted Tekmira Pharmaceuticals nonexclusive global rights to use its Unlocked Nucleobase Analog RNAi payload technology to develop RNAi drugs. The technology can help enhance the stability and reduce the undesired effects of RNAi drugs, the firms said. The deal entitles Marina to an upfront payment plus milestone fees and royalties on products arising from the collaboration. Genetic Engineering & Biotechnology News (11/29) - Researchers grow blood vessels from personalized stem cells
British researchers succeeded in developing personalized stem cells from a patient's own blood. The method involved identifying a type of repair cell in the blood and then converting these cells into stem cells. In this study, published in the journal Stem Cells: Translational Medicine, the cells were then used to grow blood vessels. Researchers said the next step is to develop the cells into clinical-grade cells. BBC (11/29) | Company & Financial News | | | | | Food & Agriculture | | | | - Journal should retract French biotech corn study, experts say
Biotech experts and scientists urged Reed Elsevier's Food and Chemical Toxicology journal, the publisher of a French study that linked Monsanto's corn to increased tumor risk in rats, to retract the paper and explain why it was published. The petition follows the European Food Safety Authority's rejection of the study's findings in its recent report, saying that the paper "does not meet acceptable scientific standards." Reuters (11/30) | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Senate votes to allow Defense Dept. to invest in biorefineries
The Senate voted 54-41 to approve an amendment that would allow the Department of Defense to invest in advanced-biofuel plants through a partnership deal involving the Agriculture, Energy and Navy departments. "Developing a commercially viable biofuels industry could help DOD diversify its fuel sources and reduce the risk of energy volatility," said Sen. Kay Hagan, D-N.C., who introduced the amendment. The Hill/Floor Action Blog (11/29)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | Silent gratitude isn't much use to anyone."
--Gladys Bronwyn Stern,
British writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, November 30, 2012
- Thursday, November 29, 2012
- Wednesday, November 28, 2012
- Tuesday, November 27, 2012
- Monday, November 26, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment